-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Maintains Buy on MapLight Therapeutics, Raises Price Target to $52

Benzinga·07/21/2026 18:32:51
Listen to the news
UBS analyst Ashwani Verma maintains MapLight Therapeutics (NASDAQ:MPLT) with a Buy and raises the price target from $48 to $52.